Hyperhomocysteine like risk factor in patient with systemic lupus erythematous with antiphospholipid sindrom
DOI:
https://doi.org/10.31053/1853.0605.v62.n1.27654Keywords:
.Abstract
Objectives: to detect the prevalence of hyperhcy lo SLE patients with and without antiphospholipid syndrom; to compare the Hcy levels between those patients and healthy controis and to determine the correlation between hyperhcy and antiphospholipid antibodies.
Patients and methods: we studied 44 SLE patients: 17 had antiphospholipid syndrom and 27 didn't have it, and we compared them to 24 hcalthy controls. All of them where checked clinically and with laboratory tests like anticardiolypin antibodies, lupus anticoagulant and Hcy. Hcy> 9 was considered abnormal. Patient who had hyperhcy were treated with folie acid+vitB6+vitBl2 a nionth along. Statistical analysis: cualytative variables: chi square or Fischer's; cuantitative variables: Student's T test or Mann- Whitney's test.
Results and conclutions: there were 35 tromhotic manifestations in 44 patients. Hyperhcy was present in 27 SLE patients (61,4%), 12 of them had antiphospholipid syndrom. Hcy concentrations patients vs.controls was statisticaly different (p=0,002). There was also stastisticaly different the bey concentration from SLE patients with SAF vs controis (p=0,003) and without SAF vs controis (p= 0.0 15). From 33 SLE patients, 20 (33%) were aCL(+). 15(75%) of them had hiperhcy
Downloads
References
Yarnell JWG, Baker lA, Sweetman PM, et al. Fibrinogen, viscosity and white blood cell counts are major risk factors for ischaemic heart disease: 1'he Cacrphilly and Speedwell Collaborative Heart Discase Studies. Circulation 1991- 83:836-44.
Boushey CL, Beresford SAA, Amen OS, MotulskyAO: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 274:1049- 1057,1995.
Boers OH. Hyperhomocysteine as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemostas 78:520-522, 1997.
Selhub 3, Jacqes PF, Bostoin AG, et al. A sso ci at ion be t w e en plasma homocysteine conceritrations and extracranial carotid artery stenosis. N Engi J Med 1995,332:286-291.
Harker LA, Ross R, Slichter SJ, Scott CR. I Ion) ocysteine-induced arteriosclerosis. The role ofendothelial ccli injury and platelet response in its genesis. J Clin Invest 1976:58:731-741.
Di Minno G, Davi G, Morgaglione M et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993: 1400- 1406.
Wang J. Dudman NPB, Wilcken DEL. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelium celis. Thromb Haemostas 1993:70:1047-1052.
Me Kully KS: Homocysteine, folate, vitamin B6 and cardiovascular disease. JAMA 279:392-393,1998.
Graham 1: Hornocysteine in health and disease. Ana Intem Mcd 131:321-330, 1999
Michelle Petri. Treatment of Systemic Lupus Erythematosus: An update. American Family Physician. June 1998..
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The generation of derivative works is allowed as long as it is not done for commercial purposes. The original work may not be used for commercial purposes.
How to Cite
